Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01924923 · ClinicalTrials.gov registry record
New Biopsy Technique for Uveal Melanoma
A clinical trial of Uveal Melanoma, sponsored by Greater Houston Retina Research.
- Completed
- Registry status
- 1
- Enrollment target
- 1
- Study location
NCT01924923 is a study of Uveal Melanoma that has completed, run by Greater Houston Retina Research. The registered enrollment target is 1 participants, below the 145-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01924923, a study of Uveal Melanoma, has completed, sponsored by Greater Houston Retina Research.
- COMPLETED
- Registry status
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study intends to investigate a new biopsy technique that will decrease the incidence of tumor cells in the biopsy tract.
Conditions Studied
Study Locations (1)
Texas
- Retina Consultants of Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01924923
The ClinicalTrials.gov registry entry for NCT01924923 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 145-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (99% lower). The listed sponsor is Greater Houston Retina Research, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT01924923 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01924923 about?
NCT01924923 is a clinical study titled "New Biopsy Technique for Uveal Melanoma". This pilot study intends to investigate a new biopsy technique that will decrease the incidence of tumor cells in the biopsy tract.
What is the current status of trial NCT01924923?
This trial is currently completed. The enrollment target is 1 participants. The study started on 2013-06. Estimated completion is 2015-03.
What conditions does trial NCT01924923 study?
This clinical trial studies the following conditions: Uveal Melanoma.
Who is sponsoring clinical trial NCT01924923?
This trial is sponsored by Greater Houston Retina Research, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01924923 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
RECRUITING · NA
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.